Alumis Inc. Common Stock (ALMS) NASDAQ
23.36
+0.47(+2.05%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
23.36
+0.47(+2.05%)
Currency In USD
| Previous Close | 22.89 |
| Open | 23.1 |
| Day High | 23.76 |
| Day Low | 22.92 |
| 52-Week High | 30.6 |
| 52-Week Low | 2.76 |
| Volume | 646,241.03 |
| Average Volume | 1.55M |
| Market Cap | 2.88B |
| PE | -8.17 |
| EPS | -2.86 |
| Moving Average 50 Days | 25.8 |
| Moving Average 200 Days | 12.23 |
| Change | 0.47 |
Alumis to Present at the Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler,
Alumis to Participate in Upcoming February Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company wil
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 09, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the clos